Unicycive therapeutics.

... Therapeutics (Nasdaq: BTAI) and 9 Meters Biopharma (Nasdaq: NMTR). Since 2014, Dr. Laumas has served on the board of directors of private and publicly ...2 days ago ... Unicycive Therapeutics Inc. The text version of this document is not available. You can access ...Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.LOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today provided an update on the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate).About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel investigational phosphate-binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.

About UNCY. unicycive therapeutics is passionate about treating kidney diseases with significant unmet medical needs. A list of the latest Unicycive Therapeutics Inc News - UNCY Stock News, Press Releases, Earnings Report, Financial Disclosures, Offerings, Acquisitions.Nov 29, 2021 · Unicycive Therapeutics, Inc. is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead product candidate, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, a patent protected, novel investigational phosphate-binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.

Dec 28, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC ...Unicycive Therapeutics (NASDAQ:UNCY) has filed to raise $25 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing treatments for various kidney ...Unicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022) Unicycive Therapeutics ( NASDAQ:UNCY ) Third Quarter 2023 Results Key Financial Results Net ...Unicycive Therapeutics shareholders should be happy with the total gain of 99% over the last twelve months. And the share price momentum remains respectable, with a gain of 214% in the last three ...

View the latest Unicycive Therapeutics Inc. (UNCY) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Sep 29, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.We're recognized as a hub of creativity and innovation. Our vision, values, talent and strategy have been purpose-built to protect the world from cardiovascular disease. To do so requires the deep passion and drive that are inherent to our team at Verve.Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Commenced Patient Dosing in MyPeak-1 TM Phase 1b Trial of TN-201 in MYBPC3-Associated Hypertrophic Cardiomyopathy Presented Positive Phase 1 Data for TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at HFSA 2023 …Noble Capital Markets 19th Annual Emerging Growth Equity Conference (NobleCon)Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has ...

LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has ...Unicycive Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume. Change versus previous month Short interest in Unicycive Therapeutics has recently increased by 18.62%, indicating that investor sentiment is decreasing significantly. Previous NextMar 31, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, a patent protected, novel investigational phosphate-binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Jul 18, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC ...Jul 13, 2021 · LOS ALTOS, Calif., July 13, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the pricing of its underwritten initial public offering of 5,000,000 units at a public offering price per unit of $5.00. Mar 9, 2023 · As of March 9, 2023, the average one-year price target for Unicycive Therapeutics is $9.56. The forecasts range from a low of $3.03 to a high of $14.18. The average price target represents an ...

Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Get Free Report) was the target of a significant growth in short interest during the month of November.As of November 15th, there was short interest ...About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia.

--Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will ...About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC ...Jul 20, 2022 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... Discover historical prices for UNCY stock on Yahoo Finance. View daily, weekly or monthly format back to when Unicycive Therapeutics, Inc. stock was issued.Mar 31, 2023 · Unicycive Therapeutics, Inc. March 31, 2023 at 7:00 AM · 11 min read. Unicycive Therapeutics, Inc. Closed transformational fundraise that included $30 million financing upfront with up to an ... We would like to show you a description here but the site won’t allow us.TTOO. T2 Biosystems, Inc. Common Stock. $0.56 +0.1067 +23.54%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market ...Dec 1, 2023 · Unicycive Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 12 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for ... As of December 4, 2023, Unicycive Therapeutics (NASDAQ: UNCY) has received positive analyst coverage and recommendations. Bruce Jackson from Benchmark has reaffirmed his Speculative Buy rating for Unicycive Therapeutics, setting a $3 price target. Additionally, EF Hutton has also reiterated its coverage of the company with a Buy recommendation.

Feb 27, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ...

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation . Sep 12, 2023. Avalo Enters into Agreement to Divest AVTX-800 Series . Sep 6, 2023. Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference . Aug 3, 2023 ...

About Unicycive Therapeutics. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is ...About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia.LOS ALTOS, Calif., Dec. 14, 2020 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced it has ...Unicycive Therapeutics, Inc. (UNCY) latest earnings report: revenue, EPS, surprise, history, news and analysis.Nov 14, 2023 · Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Source Headline; Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023 finance.yahoo.com - November 29 at 12:12 PM: Unicycive Therapeutics, Inc.: Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update finanznachrichten.de - November 18 at 9:57 AM: Unicycive …A Brief History of Unicycive Therapeutics, Inc. (UNCY) Unicycive Therapeutics, Inc. (UNCY) is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments for various diseases and conditions. The company was founded in 2015 and is headquartered in San Diego, California.Aarvik Therapeutics is pursuing exciting molecules with an improved therapeutic index for several oncology targets by combining novel modular antibody platforms with multiple target mechanisms. Aarvik antibody platforms are readily manufacturable, scalable and versatile, and offer unlimited potential through modular design. ...JuSun. Shares of kidney disease company, Unicycive Therapeutics (NASDAQ:UNCY) jump 114% premarket after the Company signed a securities purchase agreement with certain institutional investors that ...Find the latest SEC Filings data for Unicycive Therapeutics, Inc. Common Stock (UNCY) at Nasdaq.com.Unicycive Therapeutics, Inc. (UNCY) SEC Filing 8-K Material Event for the period ending Tuesday, September 5, 2023. Home. SEC Filings. Unicycive Therapeutics, Inc. (UNCY) 8-K Material Event Wed Sep 06 2023; SEC Filings. UNCY Valuations. Intrinsic Value. Financial Stability. Financial Ratios. Insider Trades.

Nov 29, 2021 · LOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today provided an update on the development and regulatory filing pathway for Renazorb (lanthanum dioxycarbonate). LOS ALTOS, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that the Company has entered into an agreement granting exclusive rights to develop, market and commercialize Renazorb® (lanthanum ...23 Oct 2023 ... Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug candidate, oxylanthanum ...Instagram:https://instagram. how to purchase walmart stockis apple stock a good buybest nft walletssnow nyse Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the ... sbux stock dividendwarrior met coal inc Unicycive Therapeutics (NASDAQ:UNCY) has filed to raise $25 million in an IPO of its common stock, according to an S-1 registration statement. The firm is developing treatments for various kidney ... currency options brokers Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, lanthanum dioxycarbonate (LDC), is a novel investigational ...Jul 13, 2021 · 13 Jul, 2021, 08:30 ET. LOS ALTOS, Calif., July 13, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc., a clinical stage biotechnology company developing therapies for patients with kidney disease ...